First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Cerus: the story is balanced — INTERCEPT kit utilization rates at existing blood center customers (volume growth from deeper penetration vs new account…
★ Analysts see FY2026 revenue reaching $253M — +22.6% growth in a single year.
What Moves the Stock
1INTERCEPT kit utilization rates at existing blood center customers (volume growth from deeper penetration vs new account additions)
2Geographic expansion milestones: regulatory approvals in new countries (China, Japan submissions pending), national health system adoption decisions (tender wins in Middle East, Asia)
3Red blood cell system adoption trajectory: RBC represents largest addressable market (~40% of transfused components) but slower adoption than platelets/plasma due to operational complexity
4Partnership announcements and royalty revenue acceleration from strategic collaborations with national blood operators
5Path to profitability visibility: quarterly progress toward breakeven EBITDA (estimated mid-2026 based on current growth trajectory)
6INTERCEPT disposable kit sales (~75-80% of revenue): single-use illumination sets and processing sets sold per blood component treated
7Royalty and license revenue (~15-20%): milestone payments and royalties from strategic partners including blood centers and national health systems
8Equipment sales and service (~5%): capital equipment placements and maintenance contracts for INTERCEPT illumination devices
growth - Investors are attracted to the recurring revenue model, expanding addressable market with RBC system adoption…
Rising rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for unprofitable growth…
Watch on earnings: Quarterly INTERCEPT kit unit volumes by product type (platelet, plasma, red blood cell) and geographic region, Customer account metrics: total active blood centers, new account additions, and average revenue per customer trends, Red blood cell system adoption rate: percentage of eligible blood centers implementing RBC pathogen reduction post-FDA approval.
One Sentence Summary:
Cerus: the story is balanced — intercept kit utilization rates at existing blood center customers (volume growth from deeper penetration vs new account additions).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.